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Abstract
Background: The prison situations are notorious for causing interruptions of tuberculosis (TB) treatment and
occurrence of unfavorable outcomes. In Ethiopian prisons, though TB treatment programs exist, treatment
outcome results and factors contributing to unsuccessful outcome are not well documented. In this study, we
assessed the treatment outcome of TB cases and identified risk factors for unsuccessful outcome in northern
Ethiopian prisons.
Methods: A retrospective record review was conducted for all prisoners diagnosed with TB between September
2011 and August 2015. Outcome variables were defined following WHO guidelines.
Results: Out of the 496 patients, 11.5% were cured, 68% completed treatment, 2.5% were lost to follow-up, 1.6%
were with a treatment failure, 1.4% died, and 15% were transferred out. All transferred out or released prisoners
were not appropriately linked to health facilities and might be lost to treatment follow-up. The overall treatment
success rate (TSR) of the 5 years was 94% among the patients who were not transferred out. The odds of unsuccessful
outcome were 4.68 times greater among re-treatment cases compared to the newly treated cases. The year of
treatment was also associated with variations in TSR; those treated during the earlier year were more likely to
have unsuccessful outcome. Sputum non-conversion at the second-month check-up was strongly associated with
unsuccessful outcome among the smear-positive cases.
Conclusions: The mean TSR of the prisoners in the study prisons was quite satisfactory when gauged against the
target level set by the End TB Strategy. However, the lack of appropriate linkage and tracking systems for those
prisoners transferred or released before their treatment completion would have a negative implication for the
national TB control program as such patients might interrupt their treatment and develop drug-resistant TB.
Being in a re-treatment regimen and sputum non-conversion at the second-month check-up were significantly
associated with unsuccessful treatment outcome among the all forms of and smear-positive TB cases,
respectively.
Keywords: Tuberculosis, Treatment outcome, Prisons, Ethiopia
* Correspondence: ingoldmlt@gmail.com
1Department of Medical Microbiology and Immunology, College of Health
Sciences, Mekelle University, PO Box 1871, Mekelle, Ethiopia
2Department of Family Medicine, Maastricht University/CAPHRI School for
Public Health and Primary Care, PO Box 616, Maastricht, the Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Adane et al. BMC Pulmonary Medicine  (2018) 18:37 
https://doi.org/10.1186/s12890-018-0600-1
Background
Globally, the burden of tuberculosis (TB) is higher in
vulnerable populations such as prisoners and is reported
to be up to 100 times higher than in the general population
[1]. In Sub-Saharan African prisons, TB remains as one of
the fastest growing epidemics [2, 3]. The high prevalence
of human immunodeficiency virus (HIV) infection and
the lack of well-organized TB diagnostic and treatment
systems [2, 4] contribute to the disproportionate burden
of TB in the Sub-Saharan African prisons.
Inadequate TB treatment will lead to the emergence
of drug-resistant strains [5]. The prison situations are
notorious for causing interruptions of TB treatment
and occurrence of unfavorable outcomes [6]. In some
prisons, up to 24% of the TB cases have been shown to
harbor multidrug-resistant TB (MDR-TB) which makes
TB control efforts very complicated [7]. In Russian and
Brazilian prisons, 12% [8] and 8% [9] of the TB cases
have been reported to default their treatment, respectively.
In a Ugandan prison, 43% of the prisoners with TB had
defaulted their treatment [10]. The TB treatment category,
HIV co-infection, smoking, alcoholism, and a lack of
family support have been indicated as factors affecting TB
treatment success in prisons [8, 9, 11].
In Ethiopian prisons, TB treatment programs exist and
are integrated within the national TB control program
where the prison health staff provides treatment based
on the national guidelines [12]. However, treatment out-
come results and the potential factors for unsuccessful
outcome are not well documented. According to a re-
port in 2013 from the prison of North Gondar, the treat-
ment success rate (TSR) of the prisoners ranged from 42
to 80% within the 10 years period [13]. However, this
study was not comprehensive in that it did not assess
the potential factors that might be affecting the treat-
ment success. Evaluating the treatment outcome results
and identifying the risk factors for the unsuccessful out-
come will help to identify the gaps between the national
TB treatment policy and practice in prisons and initiate
evidence-based interventions. This study was designed
to assess the treatment outcome of TB cases and identify
risk factors for unsuccessful outcome in northern Ethiopian
prisons.
Methods
Study setting and diagnostic criteria
This study was carried out in prisons of the Tigray
Regional State, northern Ethiopia. Out of the nine
prisons in Tigray, four prisons, located in the cities Alamata,
Humera, Mekelle and Shire, were randomly selected and
included in the study. Information regarding the TB
diagnostic and treatment services in these settings have
been described elsewhere [14]. In general, conditions of
the four prisons were comparable where the prisons
had only poorly equipped clinics staffed with diploma
holding nurses. There were also no sputum microscopy,
GeneXpert or drug susceptibility testing (DST) services
in the clinics of the prisons and the TB diagnosis relied
merely on a referral of prisoners to health facilities outside
prisons [14]. The diagnosis was carried out at the referral
sites using the direct smear microscopy and/or chest
X-ray, and pathological investigation following the
national guidelines [15]. Accordingly, a presumptive TB
case with at least two initial sputum smear examina-
tions positive for AFB (acid-fast bacilli) by direct smear
microscopy or one sputum examination positive for
AFB and having radiographic abnormalities consistent
with active pulmonary TB is considered as a smear-
positive TB (PTB+) case. A patient having symptoms
suggestive of TB with at least three initial smear exami-
nations negative for AFB on the direct microscopy and
with radiological abnormalities consistent with pulmon-
ary TB is defined as a smear-negative TB (PTB−) case.
On the other hand, if a patient has TB involving organs
other than lungs as proven by histopathological evidence
from a biopsy or based on strong clinical evidence consist-
ent with active extra-pulmonary TB (EPTB) he/she is cate-
gorized as having EPTB.
Prisoners diagnosed with TB were linked to the
directly observed treatment short-course (DOTS) clinics
of the nearby health facilities where they were registered
and started the treatment according to the national guide-
lines [15]. Afterwards, the prison health personnel col-
lected drugs weekly from such facilities and continued the
treatment within prisons. The treatment is given based
the patients’ treatment category. Newly diagnosed TB
cases are provided with the 6 months treatment regimen
where they take a combination of four drugs (rifampicin,
isoniazid, pyrazinamide, and ethambutol) during the first
2 months of the intensive phase and continue with two of
the drugs (rifampicin and isoniazid) for the remaining 4
months. On the other hand, the previously treated cases
are treated for 8 months. This regimen consists of 8 weeks
treatment with streptomycin, rifampicin, isoniazid, pyrazi-
namide, and ethambutol followed by 4 weeks treatment
with rifampicin, isoniazid, pyrazinamide, and ethambutol
during the intensive phase, followed by 5 months
with rifampicin, isoniazid, and ethambutol. Bacterio-
logical follow-up examinations (sputum smear
checkups) are done at the end of the second, fifth,
and sixth month of therapy for all new sputum-
positive patients and at the end of the intensive phase of
treatment (the third month), and at the end of the fifth
and eighth months of treatment for the previously treated
sputum smear-positive patients. The treatment follow-up
data was regularly reported back to the health facilities for
registration as the study prisons lacked standardized log-
books to register.
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Study design and data collection
This was a retrospective analysis in which the profile
and treatment outcomes of all prisoners diagnosed with
TB between September 2010 and August 2015 was
retrieved from the TB treatment follow-up clinics of the
four selected prisons. Patients’ information such as age,
sex, the type of TB case, the treatment category, the date
of treatment initiation and completion, weight at the time
of treatment initiation, HIV status, and other related data
were recorded by the prison nurses using a standardized
recording format.
Outcome definition
The referral sites and/or the DOTS centers use the
standard national TB case definitions and treatment out-
comes adopted by WHO [16]. The categories of outcome
include: cured (a TB patient who was smear- or culture-
positive at the beginning of the treatment but who became
smear- or culture negative in the last month of treatment
and on at least one previous occasion), treatment com-
pleted (finished the treatment with resolution of symptoms
but without smear or culture result), treatment failure
(remained or became smear-positive at the end of 5 months
or later), lost to follow-up (missed treatment for at least
eight consecutive weeks), transferred out (transferred to
another site during the treatment), died (patients who died
from any cause during the course of treatment). We further
grouped the outcomes into successful treatment (sum of
cured and treatment completed) and unsuccessful treat-
ment which is the sum of treatment failure, loss to follow-
up, and death as per the WHO standard definition [17].
Data analysis
Data were entered using Epi Data entry version 3.1 soft-
ware and analyzed using SPSS version 21. We compared
prisoners with unsuccessful treatment outcome with those
having successful outcome. Even though it was already
one of the elements of the unsuccessful outcome, death
was specifically considered as an additional outcome vari-
able because we were interested to see its relationship
with body weight at treatment initiation. Bivariate and
multivariate logistic regression analyses were performed
to examine the association of independent variables with
our outcome variables. Covariates with p-values of ≤0.25
and collinearity matrix index of ≤0.7 in the bivariate
analysis were considered for inclusion in the multivariate
model. A p-value of ≤0.05 was considered to define a
statistical significance.
Results
Socio-demographic and clinical characteristics
The baseline characteristics of TB patients (n = 496) are
shown in Table 1. The majority (97%) was male, and
the mean age was 30 years (range 15–18 years). Extra-
pulmonary TB patients accounted for 43% of the TB cases;
30% of total cases had PTB−. Out of the 123 (25%) PTB+
cases, repeated smear was done for 119 (97%) at the end of
the 2nd month of treatment and nine were still smear-
positive. Eleven percent of the TB cases were HIV-infected;
the co-infection rate being slightly higher among EPTB
cases (13%). However, the difference was not statistically
significant.
Table 1 Socio-demographic and clinical characteristics of the 496
















EPTB & PTB 12 (2)
Treatment category
New case 481 (97)






On ART at time/within in 3 months of TB treatment 46 (85)
Not on ART 3 (6)
Unknown 5 (9)
Use of co-trimoxazole prophylaxisa
On co-trimoxazole at time/within 3 months of TB treatment 40 (74)






aThe denominator is HIV co-infected patients (n= 54); HIV human immunodeficiency
virus, TB tuberculosis, PTB+ smear-positive pulmonary tuberculosis, PTB− smear-
negative pulmonary tuberculosis, EPTP extra-pulmonary tuberculosis
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Trend of the TB types
The 5-year trend of all the TB types is shown in Fig. 1.
The number of PTB− cases showed variation across
years steadily increasing in the recent year; more than
half of the TB cases (51.8%) were PTB− between the
September 2014 and August 2015. On the other hand,
the number of EPTB cases roughly decreased over the 5
years.
Treatment outcome and trends
The mean treatment success rate (TSR) of the 5 years
was 94% (395/422) among the patients who were not
transferred out. As shown in Fig. 2, the TSR steadily
increased from 87% during September 2010–August
2011 to 97% in September 2013–August 2014. Overall, 57
(11.5%) were cured, 338 (68%) had completed treatment,
12 (2.5%) were lost to treatment follow-up, 8 (1.6%) were
with treatment failure, 7 (1.4%) died, and 74 (15%) were
transferred out with outcome unknown. All the prisoners
transferred to other prisons or released during the course
of their TB treatment were not appropriately linked to
health facilities.
Treatment success rate and associated factors
The treatment success rate and associated predictors are
shown in Table 2. After excluding the transferred out
prisoners and dichotomizing the outcome variable,
further analysis was done for the 422 cases. In the
multivariable analysis, the odds of having unsuccessful
outcome was significantly higher among the retreatment
cases compared to the newly treated ones (AOR = 4.68;
95% CI = 1.02–21.4). Prisoners that were treated during
September 2010–August 2011 were also more likely to
have unsuccessful outcome, compared to those treated
during September 2011–August 2012 (AOR = 0.28; 95%
CI = 0.08–0.92), September 2012–August 2013 (AOR =
0.24; 95% CI = 0.06–0.98), and September 2013–August
2014 (AOR = 0.17; 95% CI = 0.05–0.67). Sputum non-
conversion at the second-month check-up was strongly
associated with unsuccessful outcome among the smear-
positive cases. There was no association between unsuc-
cessful outcome and HIV status, the weight at treatment
initiation, the study site, and the form of the TB case.
When we perform the analysis considering death as an
outcome variable, the odds of dying among patients with
a weight at initiation of <50 Kg was 8.4 times higher (OR
= 8.39; 95% CI = 1.01–70.34) compared to the other
group.
Discussion
In this study, the overall treatment success was found to
be 94% for the prisoners that complete their treatment
while in prison. However, all the prisoners transferred to
other prisons or released during their treatment were
not appropriately linked to health facilities and might be
lost to treatment follow-up. TB treatment category, the
year of treatment, and sputum non-conversion at the
second-month check-up (for smear-positive cases) were
statistically associated with unsuccessful treatment
outcome.
The observed treatment success rate (94%) is slightly
higher than the findings from similar studies in the gen-
eral population of Tigray (89.2%) [18], northeast
Ethiopia (90.1%) [19] and is in the range of the target
level set by End TB Strategy (a TSR of ≥90%) [20]. It also
remains remarkably higher than reports from Southern
(85.2%) [21], Western (70.8%) [22] and Northwest (85.6%)
[23] Ethiopia. More specifically, the loss to follow-up
Fig. 1 Trends of all forms of registered TB cases (n = 496) in the DOTs center of four northern Ethiopian prisons, 2010–2015. Aug: August, Sep:
September; PTB+: smear-positive pulmonary tuberculosis; PTB−: smear-negative pulmonary tuberculosis; EPTP: extra-pulmonary tuberculosis
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(2.5%) and death rates (1.4%) in our study are lower than
the loss to follow-up and death rates recorded in the pre-
vious studies [18, 21, 22] which ranged from 3.2 to 35.5%
and 3.3 to 58.8%, respectively. In all the above-mentioned
studies, the TSR was calculated in a similar way with our
study where the transferred out patients were not con-
sidered. The discrepancy with findings could partly be
attributed to differences in settings that might account
for the variation in the DOTs performance. In prisons,
it easier to administer DOTs and monitor the progress
as the patients are accessible to the prison health
personnel [24]. In addition, we observed that the prison
health personnel provided the TB drugs under strict
supervision not only during the first 2 months but also
during the 4 months of the continuation phase, which
might result in an increased likelihood of better treatment
outcome in prisons.
When compared with prison specific studies, the overall
TSR in this study (94%) is higher than the findings from
the prison in Gondar which ranged from 42 to 80% across
the 10 years [13]. The time difference could not exclu-
sively be the reason for this discrepancy because the TSRs
in this study were still smaller than the TSR in our study
during the years that overlapped with our study period.
Other factors such as differences in the healthcare delivery
service between the prisons of the two regions and the
commitment of the prison health personnel in delivering
the DOTS service might be possible reasons. Higher rates
of loss to follow-up were reported elsewhere in prisons in
Uganda (43.0%) [10], and Brazil (13.0%) [9]. Similarly, the
1.4% death rate observed in this study is lower than those
recorded in Ugandan (5.0%) [10], South African (1.8%)
[11] and Brazilian (2.0%) prisons [9]. One possible explan-
ation for this variation could be the difference in the
burden of HIV co-infection, which has been shown to be
associated with unsuccessful treatment outcome [19, 25].
For example, 54% of the study participants in the South
African prison [11] were co-infected with HIV [11]
whereas only 11% of the TB cases had HIV co-infection
in our study.
Our study demonstrates that the DOTS program is
effectively functioning for prisoners that complete their
TB treatment while in the study prisons. However, the
absence of appropriate linkage for those prisoners trans-
ferred to other prisons or released during their treatment
raises a public health concern. It is more likely for such
patients to end up with a loss to follow-up or treatment
failure if not death. Those patients who survived would be
at high risk to develop of drug-resistant TB [10]. This also
implies that the community would be at risk of being
infected with a resistant strain from these patients. For the
national TB program to be successful, governmental and
non-governmental organizations (NGOs) should take the
initiative in establishing improved linkage between the
prison and public health facilities. For example, a mobile-
based communication system involving the prison health
personnel, the health professionals at a public health facility,
and the released prisoners could be a good approach in
tracking released prisoners and reducing loss to treatment
follow-up [26].
In this study, as it could be expected, previously treated
cases were more likely to have unsuccessful treatment
outcome compared to new cases which is consistent with
several previous reports [11, 18]. One of the reasons could
be the high level of treatment failure and hence possible
development of drug-resistant strains in retreatment cases
[27]. In addition, patient-related behavior might also have
contributed to the unsuccessful outcome; a study indi-
cated patients that were already lost to follow-up previ-
ously could be reluctant and tend to interrupt their
treatment again [28]. Due attention should be given to
such patients to make sure that they are taking the full
Fig. 2 Trends of treatment success rate for all forms of the TB cases (n = 496) from four northern Ethiopian prisons, 2010 to 2015. Aug: August;
Sep: September; TSR: Treatment Success Rate; TB: Tuberculosis
Adane et al. BMC Pulmonary Medicine  (2018) 18:37 Page 5 of 8
course of treatment and immediate referral should be
done for MDR screening if they already had a treatment
failure. Year of treatment was also associated with varia-
tions in treatment outcome; in general, those treated
during the earlier year (September 2010–Augst 2011)
were more likely to have unsuccessful outcome compared
to the latest years, indicating improvements in the DOTS
performance over years. This could be due to the
increasing efforts of the national TB control program
in introducing and implementing the TB/HIV collab-
orative activities in healthcare settings and prisons in
recent years [29].
Table 2 Factors related to unsuccessful treatment outcome among northern Ethiopian prisoners with tuberculosis in the bivariate and
multivariate logistic regression analysis (n = 422). AOR: adjusted odds ratio; COR: crude odds ratio; CI: confidence interval; ref = reference






Female 2 (14.3) 12 (85.7) 2.56 (0.54-12.04) 0.26 -
Male 25 (6.2) 383 (93.8) ref
Age, years
15-24 8 (4.6) 164 (95.4) 0.62 (0.23-1.71) 0.36 -
25-34 11 (7.9) 129 (92.1) 0.86 (0.86-1.09)
> 35 8 (7.3) 102 (92.7) ref
Weight at initiation (Kg)
< 50 15 (8.4) 164 (91.6) 1.76 (0.83-3.86) 1.72 (0.75-3.98) 0.2
> 50 12 (4.9) 231 (95.1) ref
Form of TBa
PTB+ 8 (7.6) 97 (92.3) 1.22 (0.48-3.14) 0.48 -
PTB - 8 (6.1) 124 (93.9) 0.96 (0.37-2.45) 0.38
EPTP 11 (6.3) 163 (93.7) ref
Non-conversion at the 2nd monthb
Yes 2 (12.5) 4 (87.5) 9.1 (1.33-62.16) 0.02 -
No 5 (5.2) 91 (94.8)
Type of TB case
Retreatment case 3 (25.0) 9 (75.0) 5.36 (1.36-21.11) 0.01 4.68 (1.02-21.4) 0.04
New case 24 (5.8) 386 (94.2) ref
HIV statusC
Positive 4 (8.5) 43 (91.5) 1.36 (0.45-4.14) 0.58 -
Negative 23 (6.4) 338 (93.6) ref
Year
Sep 2010-Aug 2011 10 (13.3) 65 (86.7) ref
Sep 2011-Aug 2012 5 (5.8) 81 (93.2) 0.41 (0.13-1.23) 0.11 0.28 (0.08-0.92) 0.04
Sep 2012-Aug 2013 3 (4.2) 69 (95.8) 0.28 (0.07-1.07) 0.06 0.24 (0.06-0.98) 0.047
Sep 2013-Aug 2014 3 (3.0) 97 (97.0) 0.21(0.05-0.76) 0.018 0.17 (0.05-0.67) 0.01
Sep 2014-Aug 2015 6 (6.7) 83 (93.3) 0.48 (0.16-1.36) 0.16 0.45 (0.14-1.43) 0.18
Site
Mekelle 12 (8.6) 127 (91.4) ref
Alamata 1 (1.4) 72 (98.6) 0.15 (0.02-1.15) 0.07 0.14 (0.02-1.18) 0.07
Shire 5 (6.8) 68 (93.2) 0.78 (0.26-2.30) 0.65 0.53 (0.16-169) 0.28
Humera 9 (6.6) 128 (93.4) 0.74 (0.3-1.83) 0.52 0.64 (0.23-1.72) 0.38
aPatients with both PTB & EPTB were not included; bAnalysis limited to the smear-positive cases; cAnalysis limited to patients with known HIV status; HIV human
immunodeficiency virus; Kg kilogram; PTB+ smear-positive pulmonary tuberculosis; PTB- smear-negative pulmonary tuberculosis; EPTB extra-pulmonary
tuberculosis
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Unlike several previous reports [11, 19, 25], in this study,
HIV co-infection was not associated with unsuccessful out-
come. The difference in the sample size and burden of the
co-infection rate might be possible reasons for this. In
addition, the prison health personnel reported that they
routinely supervise the TB treatment progress of prisoners
including those co-infected with HIV which might have
contributed to the improved outcome in both groups.
Though it was not associated with unsuccessful outcome,
body weight at initiation of anti-TB treatment (<50 Kgs)
was found to be a significant predictor of death of the
patients, which is in agreement with previous reports
[30, 31]. The relationship between TB and malnutrition
is bidirectional. Severe TB disease renders patients to
be malnourished and malnourished individuals are at a
high risk to develop severe TB diseases and end up with
unfavorable treatment outcomes [32]. Hence, the death
of patients might be attributed to the severity of the TB
disease itself or due to the malnutrition and associated
consequences. Closer nutritional monitoring and earlier
initiation of nutrition support are important to rescue
severely malnourished TB patients [32]. In smear-positive
cases, sputum non-conversion at the second-month check-
up was a predictor of unsuccessful outcome. This might be
partly related to the drug resistance development. In 2015,
the incidence of multidrug-resistant/rifampicin-resistant
(MDR/RR-TB) in Ethiopia was estimated to be 2.7%
among the new and 14% among retreatment TB cases
[20]. In the Tigray region of Ethiopia, 55% of the pre-
sumptive MDR cases have been shown to harbor MDR
strains [33]. We suggest that such prisoners should be
immediately referred for DST.
Furthermore, an overview of the TB profile data showed
that the majority of the patients in our study were EPTB
and PTB− cases, which is consistent with the previous
reports from the general population in Ethiopia [34, 35].
The exact causes for the high proportion of EPTB in
Ethiopia remain unknown, however, the high potential for
a wrong diagnosis (due to the poor diagnostic facility),
and poor immunologic and nutritional status have been
shown to be associated with high rates of EPTB and PTB−
cases [36, 37]. This might suggest the need to incorporate
a more accurate diagnostic test, such as the GeneXpert
MTB/RIF assay, in Ethiopian prisons.
This study has some limitations mainly inherited
from the retrospective design. As we relied on histor-
ical records, we were not able to add some important
variables such as alcoholism, smoking, substance
abuse, nutritional status, and lack of family support,
which are known to be related to the variations in the
TB treatment outcome [38]. Tracking the prisoners
transferred between prisons was also not possible, as
the information was not clearly indicated in the treatment
recording protocol.
Conclusions
The mean treatment success rate of the prisoners in the
study prisons was quite satisfactory when gauged against
the target level set by the End TB Strategy. However, the
lack of appropriate linkage and tracking systems for
those prisoners transferred or released before their treat-
ment completion would have a negative implication for
the national TB control program as such patients might
interrupt their treatment and develop drug-resistant
TB. Being in a re-treatment regimen and sputum non-
conversion at the second-month check-up were signifi-
cantly associated with unsuccessful outcome among all
forms of and smear-positive TB cases, respectively. The
concerned authorities should take an urgent action to
help establish improved linkages between the prison
and public health facilities to prevent possible loss to
follow-up of released prisoners and due attention should
be given to the previously treated cases.
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